Publication | Closed Access

Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)

OncologyGastrointestinal OncologyMedicineColorectal CancerPathologyPhase Ii StudyWjog 6510GCancer TreatmentPharmacologyRadiation OncologyIrinotecan Versus Cetuximab